Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Anebulo Pharmaceuticals Inc
Income from Continuing Operations
Anebulo Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
Income from Continuing Operations
-$11.7m
|
CAGR 3-Years
-310%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Anebulo Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-11.7m
USD
Based on the financial report for Jun 30, 2023, Anebulo Pharmaceuticals Inc's Income from Continuing Operations amounts to -11.7m USD.
What is Anebulo Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-310%
Over the last year, the Income from Continuing Operations growth was -72%. The average annual Income from Continuing Operations growth rates for Anebulo Pharmaceuticals Inc have been -310% over the past three years .